MaxCyte Signs Strategic Platform License With Imugene; Imugene Obtains Non-Exclusive Clinical And Commercial Rights To Use MaxCyte's Flow Electroporation Technology And ExPERT Platform; MaxCyte Receives Platform Licensing Fees And Program-Related Revenue
Portfolio Pulse from Benzinga Newsdesk
MaxCyte has entered into a strategic licensing agreement with Imugene, granting Imugene non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation Technology and ExPERT platform. In return, MaxCyte will receive platform licensing fees and program-related revenue.
January 23, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MaxCyte's strategic licensing deal with Imugene is expected to generate additional revenue for the company through licensing fees and program-related payments.
The agreement with Imugene is likely to have a positive short-term impact on MaxCyte's stock price as it opens up a new revenue stream through licensing fees and program-related revenue. The deal demonstrates the value and demand for MaxCyte's technology, which could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80